高危唾液腺肿瘤患者术后同期放化疗前瞻性Ⅱ期临床试验研究

doi:10.3760/cma.j.issn.1004-4221.2020.03.002

Abstract
Figure/Table
References(32)
Related Citation (15)
Read Tracking
Download Tracking

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS) Supporting Info

Abstract Objective To assess the efficacy and safety of post operative adjuvant concurrent chemoradiotherapy for patients with high-risk salivary gland tumors (SGT). Methods Fifty-two patients with moderate or high malignant pathological stage complicated with locally advanced stage Ⅲ/ⅣA±positive margin/close margin admitted to Shanghai Ninth People′s Hospital from 2016 to 2018 were enrolled in this study. Among them, 35 patients were male and 17 female with a median age of 55.5 years old (range:21-73 years old). All 52 patients were treated with intensity-modulated radiotherapy and concurrent chemotherapy. Patients with adeno carcinoma of the salivary gland receives concurrent chemotherapy with TP regimen. Patients with lympho epithelial cancer and squamous cell carcinoma were treated with cisplatin regimen.Results Forty-seven patients (90%) completed two cycles of concurrent chemotherapy,and five patients (10%) completed one cycle of concurrent chemotherapy. The median follow-up time was 15.7 months (3.2-34.8 months). The 2-year disease-free survival (DFS) and overall survival (OS) rates were 74% and 98%. Three patients experienced regional lymph recurrence and 6 cases had distant metastasis. Grade Ⅲ oral mucositis was observed in 30 patients. Grade Ⅲ dermatitis occurred in 5 cases. Only one patient experienced Grade IV neutropenia,and 2 patients developed Grade Ⅲ neutropenia. DFS was positively correlated with the cycle of postoperative adjuvant concurrent chemotherapy (P=0.006).Conclusions Patients with high-risk SGT can obtain higher 2-year DFS and OS rates and tolerable adverse events after postoperative concurrent chemoradiotherapy. Nevertheless, the long-term outcomes remain to be validated by randomized controlled clinical trials.

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Wang Xin
	Dou Shengjin
	Li Rongrong
	Wu Sicheng
	Chen Gang
	Zhang Lin
	Yang Wenjun
	Zhu Guopei

Key words： High-risk salivary gland tumor Postoperative adjuvant Concurrent chemoradiotherapy Prospective study

Received: 12 May 2019

Fund:Clinical Project of Shanghai Municipal Commission of Health (201640158)

Corresponding Authors: Zhu Guopei,Email:antica@gmail.com

Cite this article:

Wang Xin,Dou Shengjin,Li Rongrong et al. Prospective phase Ⅱ study of postoperative concurrent chemoradiotherapy for patients with high-risk malignant salivary gland tumors[J]. Chinese Journal of Radiation Oncology, 2020, 29(3): 166-170.

URL:

http://journal12.magtechjournal.com/Jweb_fszlx/EN/10.3760/cma.j.issn.1004-4221.2020.03.002 OR http://journal12.magtechjournal.com/Jweb_fszlx/EN/Y2020/V29/I3/166

[1] Ettl T,Schwarz-Furlan S,Gosau M,et al. Salivary gland carcinomas[J]. Oral Maxillofac Surg 2012,16:267–283. DOI:10.1007/s10006-012-0350-9.
[2] EI-Naggar AK,Chan JK,Grandis JR,et al. WHO classification oftumors of head and neck tumours[M].4th ed. Lyon:IARC Press,2017:159-201.
[3] Cooper JS,Pajak TF,Forastiere AA,et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck[J]. N Engl J Med,2004,350(19):1937-1944. DOI:10.1056/NEJMoa032646.
[4] Bernier J,Domenge C,Ozsahin M,et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer[J]. N Engl J Med,2004,350:1945-1952. DOI:10.1056/NEJMoa032641.
[5] Terhaard CH,Lubsen H,Van der Tweel I,et al. Salivary gland carcinoma:independent prognostic factors for locoregional control,distantmetastases,and overall survival:Results of the dutch head and neck oncology cooperative group[J]. Head Neck,2004,26(8):681-693. DOI:10.1002/hed.10400.
[6] Guzzo M,Locati LD,Prott FJ,et al. Major and minor salivary gland tumors[J]. Crit Rev Oncol Hematol,2010,74:134-148. DOI:10.1016/j.critrevonc.2009.10.004.
[7] Harrison LB,Armstrong JG,Spiro RH,et al. Postoperative radiation therapy for major salivary gland malignancies[J]. J Surg Oncol,1990,45:52-55. DOI:10.1002/jso.2930450112.
[8] Cheung MC,Franzmann E,Sola JE,et al. A comprehensive analysis of parotid and salivary gland cancer:worse outcomes for male gender[J]. J Surg Res,2011,171(1):151-158. DOI:10.1016/j.jss.2009.11.721.
[9] Bell RB,Dierks EJ,Homer L,et al. Management and outcome of patients with malignant salivary gland tumors[J]. J Oral Maxillofac Surg,2005,63(5):917-928. DOI:10.1016/j.joms.2005.03.006.
[10] Pignon JP,leMaitre A,Maillard E,et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC):an update on 93 randomised trials and 17,346 patients[J]. Radiother Oncol,2009,92(1):4-14. DOI:10.1016/j.radonc.2009.04.014.
[11] Airoldi M,Cortesina G,Giordano C,et al. Update and perspectives on non-surgical treatment of salivary gland malignancies[J]. Acta Otorhinolaryngol Ital,2003,23(2):368-376.
[12] Gilbert J,Li Y,Pinto HA,et al. Phase Ⅱ trial of taxol in salivary gland malignancies (E1394):a trial of the Eastern Cooperative Oncology Group[J]. Head Neck,2006,28(1):197-204. DOI:10.1002/hed.20327.
[13] Van Herpen CML,Locati LD,Buter J,et al. PhaseⅡ study on gemcitabine in recurrent and/or metastatic adenoid cystic carcinoma of the head and neck (EORTC 24982)[J]. Eur J Cancer,2008,44:2542-2545. DOI:10.1016/j.ejca.2008.08.014.
[14] Airoldi M,Pedani F,Succo G,et al. PhaseⅡ randomized trial comparing vinorelbine versus vinorelbine plus cisplatin in patients with recurrent salivary gland malignancies[J]. Cancer,2001,91(3):541-547. DOI:10.1002/1097-0142(20010201)91:3<541:AID-CNCR1032>3.0. CO;2-Y.
[15] Lagha A,Chraiet N,Ayadi M,et al. Systemic therapy in the management of metastatic or advanced salivary gland cancers[J]. Head Neck Oncol,2012,4(1):19. DOI:10.1186/1758-3284-4-19.
[16] Kaplan MJ,Johns ME,Cantell R,et al. Chemotherapy for salivary gland cancer[J]. Otolaryngol Head Neck Surg,1986,95(1):165-170. DOI:10.1177/019459988609500206.
[17] Suen JY,Johns M. Chemotherapy for salivery gland cancer[J]. Laryngoscope,1982,92(3):235-239. DOI:10.1288/00005537-198203000-00003.
[18] Laurie SA,Ho AL,Fury MG,et al. Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands:a systematic review[J]. Lancet Oncol,2011,12(8):815-824. DOI:10.1016/S1470-2045(10)70245-X.
[19] Dreyfuss AI,Clark JR,Fallon BG,et al. Cyclophosphamide,doxorubicin,and cisplatin combination chemotherapy for advanced carcinomas of salivary gland origin[J]. Cancer,1987,60(12):2869-2872. DOI:10.1002/1097-0142(19871215)60:12<2869::AID-CNCR2820601203>3.0. CO;2-Y.
[20] Creagan ET,Woods JE,Rubin J,et al. Cisplatin based chemotherapy for neoplasms arising from salivary glands and contiguous structures in the head and neck[J]. Cancer,1988,62(12):2313-2319. DOI:10.1002/1097-0142(19881201)62:11<2313:AID-CNCR2820621110>3.0. CO;2-4.
[21] Kasibhatla M,Kirkpatrick JP,Brizel DM. How much radiation is the chemotherapy worth in advanced head and neck cancer?[J]. Int J Radiat Oncol Biol Phys,2007,68(8):1491-1495. DOI:10.1016/j.ijrobp.2007.03.025
[22] Fowler JF. Correction to Kasibhatla et al. How much radiation is the chemotherapy worth in advanced head and neck cancer?[J]. Int J Radiat Oncol Biol Phys,2008,71(2):326-329. DOI:10.1016/j.ijrobp.2008.01.052.
[23] Pederson AW,Salama JK,Haraf DJ,et al. Adjuvant chemoradiotherapy for locoregionally advanced and high-risk salivary glandmalignancies[J]. Head Neck Oncol,2011,3(1):31. DOI:10.1186/1758-3284-3-31.
[24] Rosenberg L,Weissler M,Hayes DN,et al. Concurrent chemoradiotherapy for locoregional advanced salivary gland malignancies[J]. Head Neck,2012,34(5):872-876. DOI:10.1002/hed.21831.
[25] Schoenfeld JD,Sher DJ,Norris CM Jr,et al. Salivary gland tumors treated with adjuvant intensity-modulated radiotherapy with or without concurrent chemotherapy[J]. Int J Radiat Oncol Biol Phys,2012,82(2):308-314. DOI:10.1016/j.ijrobp.2010.09.042.
[26] Tanvetyanon T,Qin D,Padhya T,et al. Outcomes of postoperative concurrent chemoradiotherapy for locally advanced major salivary gland carcinoma[J]. Arch Otolaryngol Head Neck Surg,2009,135(7):687-692. DOI:10.1001/archoto.2009.70.
[27] Mifsud MJ,Tanvetyanon T,Mccaffrey JC,et al. Adjuvant radiotherapy versus concurrent chemoradiotherapy for the management of high-risk salivary gland carcinomas[J]. Head Neck,2016,38(11):1628-1633. DOI:10.1002/hed.24484.
[28] Gebhardt BJ,Ohr JP,Ferris RL,et al. Concurrent Chemoradiotherapy in the adjuvant treatment of high-risk primary salivary gland malignancies[J]. Am J Clin Oncol,2018,41(9):888-893. DOI:10.1097/COC.0000000000000386.
[29] Maruya S,Namba A,Matsubara A,et al. Salivary gland carcinoma treated with concomitant chemoradiation with intraarterial cisplatin and docetaxel[J]. Int J Clin Oncol,2006,11(5):403-406. DOI:10.1007/s10147-006-0587-0.
[30] Airoldi M,Fornari G,Pedani F,et al. Paclitaxel and carboplatin for recurrent salivary gland malignancies[J]. Anticancer Res,2000,20(5C):3781-3783. DOI:10.1097/00001813-200009000-00012.
[31] Li R,Dou S,Ruan M,et al. A feasibility and safety study of concurrent chemotherapy based on genetic testing in patients with high-risk salivary gland tumors[J]. Medicine,2018,97(17):e0564. DOI:10.1097/MD.0000000000010564.
[32] Szewczyk M,Golusinski P,Pazdrowski J,et al. Patterns of treatment failure in salivary gland cancers[J]. Rep Pract Oncol Radiother,2018,23(2):260-265. DOI:10.1016/j.rpor.2018.05.004.